Search
Olmutinib
go.drugbank.com/drugs/DB13164InvestigationalIt is available under the brand name Olita made by Hanmi Pharmaceuticals [A19196]. Olmutinib was developed by Hanmi Pharmaceuticals and Boehringer Ingelheim.
Plazomicin
go.drugbank.com/drugs/DB12615ApprovedDeveloped by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from [DB12604]. … It mediates the antibacterial activity by binding to bacterial 30S ribosomal subunit and inhibiting protein synthesis [FDA Label].
Categories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic IndexRucaparib
go.drugbank.com/drugs/DB12332ApprovedInvestigationalPARP is an enzyme that plays an essential role in DNA repair. … By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexSutimlimab
go.drugbank.com/drugs/DB14996ApprovedInvestigational[A245144] It received FDA approval in February 2022, under the brand name Enjamyo (sutimlimab-jome), becoming the first approved therapy for patients with CAD. … [L40114,A245144] Sutimlimab was also approved by the European Commission in November 2022.[L44116]
Niraparib
go.drugbank.com/drugs/DB11793ApprovedInvestigationalBy blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells.[L43277] Niraparib is selective towards PARP-1 and PARP-2. … [A253248] First approved by the FDA on March 27, 2017,[A253912] niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Categories: MATE 1 Substrates with a Narrow Therapeutic Index, MATE 2 Substrates with a Narrow Therapeutic IndexDanaparoid
go.drugbank.com/drugs/DB06754ApprovedWithdrawnDanaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans [A32565]. … Danaparoid possesses a potent antithrombic activity that works by inhibiting activated factor X (Factor Xa) and activated factor II (Factor IIa).
Talimogene laherparepvec
go.drugbank.com/drugs/DB13896ApprovedInvestigationalIt was approved by the FDA in 2015 under the market name Imlygic. In general, talimogene laherparepvec has been modified so that it can infect and multiply inside melanoma cells [L2221]. … It is a genetically administered herpes simplex virus 1 (HSV-1) that expresses human cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with antitumor and immune-stimulating activities.
Categories: DNA VirusesTiapride
go.drugbank.com/drugs/DB13025InvestigationalTiapride is a selective D2 and D3 dopamine receptor blocker in the brain.
Categories: Dopamine D2 Receptor AntagonistsProducts: TIAPRID 1A PHARMA 200MG, TIAPRID 100 1A PHARMAGepotidacin
go.drugbank.com/drugs/DB12134ApprovedInvestigationalGepotidacin is a first-in-class triazaacenaphthylene antibacterial targeting bacterial DNA gyrase and topoisomerase IV.[L52685] Its target is similar to that of fluoroquinolone antibacterials - e.g. … [A273755] By inhibiting two distinct bacterial enzymes, a lower potential for the development of resistance to gepotidacin is expected.
Obeticholic acid
go.drugbank.com/drugs/DB05990ApprovedInvestigationalhepatic decompensation) due to a risk of liver failure, in some cases requiring liver transplantation. … [A192786] Obeticholic acid is a farnesoid-X receptor (FXR) agonist used to treat this condition, possibly allowing for increased survival.